Thus, the activities of CYP1A2 and CYP3A4 are decreased in CKD and are expected to have significant clinical implications, with altered drug pharmacokinetics and increased adverse drug events in patients with CKD. This evidence concerns the gene CYP3A4 and chronic kidney disease.